CA-PULMONX
18.11.2016 20:28:12 CET | Business Wire | Press release
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) this week issued a substantial revision to its management recommendations for chronic obstructive pulmonary disease (COPD) that, for the first time, includes bronchoscopic lung volume reduction using endobronchial valves as a treatment option for patients with advanced emphysema and absence of collateral ventilation. The updated recommendations are based on new clinical evidence published in the past 15 months supporting the Zephyr® Endobronchial Valve (EBV), including three randomized controlled trials (BeLieVeR-HIFi , STELVIO and IMPACT ).
In describing the clinical evidence to support this recommendation, the GOLD report notes, “In select patients with advanced emphysema, bronchoscopic interventions reduce end-expiratory lung volume and improves exercise tolerance, health status and lung function 6-12 months following treatment.“
“This is the first major update to the GOLD guidance for bronchoscopic interventions, based on recent data,” said Professor Felix Herth, Head of the Department of Internal Medicine, Pulmonology and Critical Care Medicine, Thoraxklinik Heidelberg, Germany. “These interventions offer promise for emphysema patients who continue to suffer symptoms, despite optimal pharmacologic management.”
Zephyr EBVs are tiny, minimally-invasive, one-way valves placed in select airways of the lungs to occlude diseased regions and reduce lung hyperinflation. As a result, the remaining healthier regions may function more efficiently, enabling better breathing and an improved quality of life for patients.
Each year, GOLD issues a report entitled “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease,” which is used worldwide as a “strategy” document for healthcare professionals to implement effective management programs based on local healthcare systems. The report issues recommendations for the management of COPD based on the best scientific information available.
“With our tools to help physicians identify the best responders to endobronchial valve treatment, Pulmonx is enabling precision medicine for the treatment of emphysema,” said Glen French, Pulmonx chief executive officer. “We welcome this recognition of the growing body of evidence demonstrating the benefit of EBV treatment for emphysema patients.”
Over the past 10 years, more than 48,000 Zephyr EBVs have been implanted globally in more than 12,000 patients. To view a video of the Zephyr EBV procedure, click here .
About Pulmonx
Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is an interventional pulmonology company focused on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide. For more information, visit www.pulmonx.com .
The Zephyr EBV is an investigational device in the United States. Limited by U.S. law to investigational use only.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161118005704/en/
Contact:
Chronic Communications
Michelle McAdam, (949) 545-6654 or (310)
902-1274
michelle@chronic-comm.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group Announces New Chair and Vice Chair20.5.2026 11:00:00 CEST | Press release
Highlights:Planned transition in the Chair and Vice Chair roles reflects the Chiesi family’s long-term commitment to continuity, shared value and responsible governance across generationsMaria Paola Chiesi is appointed Chair, the first woman in this role; aims to reinforce sustainability as an integral and enduring pillar of the Group’s strategy Chiesi today announced a planned leadership change in its Board of Directors: Maria Paola Chiesi has been appointed Chair of the Board, succeeding Alessandro Chiesi, who is completing his tenure after nearly three years in the role, and will now continue to serve as Vice Chair. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520447292/en/ Maria Paola Chiesi is appointed Chair of Chiesi Board of Directors, the first woman in this role; aims to reinforce sustainability as an integral and enduring pillar of the Group’s strategy During his mandate, Alessandro Chiesi oversaw the Group t
Insurance Investment Outsourcing Surpasses $5.5 Trillion as Private Markets and Global Expansion Reshape the Industry20.5.2026 09:00:00 CEST | Press release
IIOR Shows Record Outsourced Insurance AUM, Private Assets Near $1 Trillion, and Europe Emerging as a Global Growth Engine Clearwater Analytics (NYSE: CWAN) today released the 2026 Insurance Investment Outsourcing Report (IIOR), produced in partnership with DCS Financial Consulting. The report captures $5.5 trillion in third-party general account insurance assets under management across 96 asset managers, a 23% increase year-over-year and a 65% increase since 2021, alongside $1.8 trillion in assets under advisement across 12 investment consultants. The findings point to an outsourcing market that has become larger, more global, and materially more complex. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520780028/en/ The 2026 IIOR reveals defining trends reshaping insurance investment management: Private Markets Cross a Threshold. Third-party private insurance AUM has more than doubled since 2021, reaching $947 billion and
Factbird Adds Quality & Compliance and Reports to its Manufacturing Intelligence Platform20.5.2026 08:00:00 CEST | Press release
Two new capabilities give multi-site manufacturers standardized workflows, traceable records, and automated reporting across every plant. Today, Factbird is announcing two major additions to its manufacturing intelligence platform: Quality & Compliance and Factbird Reports. Both address a problem that compounds as manufacturers grow. More sites mean more variation in how work gets done. More regulation means more documentation pressure on frontline teams. And more data, when fragmented across systems, often slows decisions rather than speeding them up. Solving this has traditionally meant large IT projects and months of deployment. “Enterprise manufacturers shouldn’t have to choose between capability and simplicity,” said Mogens Arne Hansen, Chief Technology and Product Officerat Factbird. “With Quality & Compliance and Reports, you can have standardized, audit-ready operations and automated performance reporting across every site, deployed in days, used by the people on the floor.” Qu
The LYCRA Company to Successfully Complete Comprehensive Financial Restructuring20.5.2026 04:23:00 CEST | Press release
Company positioned for long-term growth, operational excellence, and continued customer-focused innovationWill emerge from financial restructuring with enhanced financial flexibility and significantly less debtNew ownership and Board of Directors committed to executing on vision to take the business to the next levelBruce Rubin appointed Executive Chairman and Dean Williams appointed Interim Chief Executive Officer The LYCRA Company, LLC (“the Company”), a global leader in developing fiber and technology solutions for the apparel and personal care industries, will successfully complete its comprehensive financial restructuring process and emerge from Chapter 11 protection on May 20, 2026. The LYCRA Company has established a durable capital structure that will enable the Company’s pursuit of its growth strategy through investment in innovation, customer partnerships, and global operations. The Company will emerge from its comprehensive restructuring process with significantly enhanced f
Johns Manville Announces John Vasuta as New CEO19.5.2026 22:30:00 CEST | Press release
Johns Manville (JM), a global building and specialty products manufacturer and a Berkshire Hathaway company, announced today that Bob Wamboldt will retire and John Vasuta will assume the role of President and Chief Executive Officer, effective August 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519630814/en/ John Vasuta will become JM's CEO and President on August 1, 2026. Vasuta joined Johns Manville in 2019 as President of the company’s Engineered Products business. He also serves on the Board of Directors for EJ, a global leader and private manufacturer of infrastructure access products for water, sewer, utilities, drainage and telecommunications. “It’s an extraordinary privilege to step into the role of CEO,” Vasuta said. “I’m deeply honored to continue serving our customers and supporting the employees whose dedication makes our success possible.” Before joining JM, John held leadership roles at Bridgeston
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom